Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

DraftKings (NASDAQ: DKNG) is forecasting robust growth in revenue and profitability in 2025. Read More: Earn up to $845 cash ...

Valued at a market cap of $518 million, Luminar Technologies (LAZR) is an automotive company that provides sensor ...

Investors must decide how to proceed with Apple near all-time highs and a significant stakeholder selling shares.

CAT's Q3 earnings and revenue guidance disappoints, with a weak end-user demand impacting volumes. Shares of the company dip ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

Entergy has strong growth potential but appears overvalued. See why ETR stock’s favorable regulatory environment and dividend ...

Despite volatility in gold prices, the sustained revenue momentum in Q2 was led by robust footfall post custom duty cut from ...

Stock Market Today: Adani Power share price gained more than 7% in morning trades on Wednesday. Adani power recently ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Investors who are skeptical about whether Carnival can sail through a storm could find a reason to disembark and sell the ...

Source: Finbold Why Nvidia stock is not as no-brain a buy as you might think The historical performance and momentum point toward Nvidia being a no-brain hold for those who hold ... there are no sell ...